
985
Downloads
47
Episodes
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Episodes
Mar 2, 2026
Mar 2, 2026
19 min
E36 | 20 min | Latest | Publication Link
- Podcast based on: Fan, R.; Wei, X.; Lea, J.; Zhu, H.; Zheng, W. ER-Negative Endometrial Cancers: An Evolving Diagnostic Category with Major Clinical Implications. Cancers 2026, 18, 773. https://doi.org/10.3390/cancers18050773
Type: Review | Publication date: 27 February 2026 - Summary: Estrogen receptor–negative (ER-negative) endometrial carcinomas represent a biologically aggressive and heterogeneous subset of endometrial cancers. Although ER testing has long been used in endometrial carcinoma, it has historically been applied mainly for therapeutic decision-making rather than as a diagnostic tool. Loss of ER expression is associated with poor prognosis but, by itself, is insufficient for accurate tumor classification. In this commentary, we review the evolving diagnostic significance of ER negativity using an integrated framework that incorporates tumor morphology, immunophenotypic features, and molecular heterogeneity. We highlight several high-grade ER-negative tumor types—including gastrointestinal-type adenocarcinoma, pilomatrix-like carcinoma, mesonephric-like adenocarcinoma, clear cell carcinoma, and other high-grade ER-negative carcinomas—that show distinct clinicopathologic characteristics. We propose that ER negativity should be regarded as a diagnostic signal that prompts careful subclassification, with important implications for accurate diagnosis and clinical management.
- Keywords: estrogen receptor–negative (ER-negative) endometrial carcinomas; endometrial gastrointestinal-type adenocarcinoma; pilomatrix-like high-grade endometrial carcinoma; PiMHEC; mesonephric-like adenocarcinoma
License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.
Mar 2, 2026
19 min

No comments yet. Be the first to say something!